alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```
[Federal Register Volume 63, Number 75 (Monday, April 20, 1998)]
[Notices]
[Page 19521]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-10282]

-----------------------------------------------------------------------

DEPARTMENT OF LABOR

Pension and Welfare Benefits Administration

Working Group Studying Pre-Retirement Distributions From ERISA 
Employer-Sponsored Pension Plans Advisory Council on Employee Welfare 
and Pension Benefits Plans; Notice of Meeting

    Pursuant to the authority contained in Section 512 of the Employee 
Retirement Income Security Act of 1974 (ERISA), 29 U.S.C. 1142, a 
public meeting will be held on Tuesday, May 5, 1998 of the new Working 
Group of the Advisory Council on Employee Welfare and Pension Benefit 
Plans, which will study pre-retirement distributions, including in-
service distributions and participant loans from ERISA employer-
sponsored pension plans, known in the pension benefits community as 
``leakage.''
    The purpose of the open meeting, which will run from 9:30 a.m. to 
approximately noon on Room N-4437 C&D, U.S. Department of Labor 
Building, Second and Constitution Avenue NW, Washington, DC 20210, is 
for Working Group members to establish the agenda and course of study 
for the upcoming Council year on the topic. The Working Group Chair 
Barbara A. Uberti, vice president of the Wilmington Trust Company in 
Wilmington, Del., and Vice Chair Michael R. Fanning, chief executive 
officer of the Central Pension Fund International Union of Operating 
Engineers and Participating Employers, Washington, DC, hope to begin 
hearing testimony on the topic at the first session.
    Members of the public are encouraged to file a written statement 
pertaining to the topic by submitting 20 copies on or before May 1, 
1998, to Sharon Morrissey, Executive Secretary, ERISA Advisory Council, 
U.S. Department of Labor, Room N-5677, 200 Constitution Avenue, NW, 
Washington, DC 20210. Individuals or representatives of organizations 
wishing to address the Working Group should forward their request to 
the Executive Secretary or telephone (202) 219-8753. Oral presentations 
will be limited to 10 minutes, but an extended statement may be 
submitted for the record. Individuals with disabilities, who need 
special accommodations, should contact Sharon Morrissey by May 1, 1998, 
at the address indicated in this notice.
    Organizations or individuals also may submit statements for the 
record without testifying. Twenty (20) copies of such statements should 
be sent to the Executive Secretary of the Advisory Council at the above 
address. Papers will be accepted and included in the record of the 
meeting if received on or before May 1.

    Signed at Washington, D.C. this 13th day of April, 1998.
Olena Berg,
Assistant Secretary, Pension and Welfare Benefits Administration.
[FR Doc. 98-10282 Filed 4-17-98; 8:45 am]
BILLING CODE 4510-29-M
```
EXHIBIT 23

[LETTERHEAD OF CLARK, SCHAEFER, HACKETT & CO.]

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM

Board of Directors

United Community Bancorp

Lawrenceburg, Indiana

We consent to
incorporation by reference in Registration Statement No. 333-132939 on Form S-8 of United Community Bancorp of our Report of Independent Registered Public Accounting Firm, dated September 24, 2007, on the consolidated balance sheets of
United Community Bancorp as of June 30, 2007 and 2006, and the related consolidated statements of income, comprehensive income, stockholders equity and cash flows for the three years in the period ended June 30, 2007 which reports
appear in the 2007 annual report on Form 10-K of United Community Bancorp.



/s/ Clark, Schaefer, Hackett & Co.Clark, Schaefer, Hackett & Co.


Cincinnati, Ohio

September 24, 2007
[Federal Register Volume 62, Number 75 (Friday, April 18, 1997)]
[Notices]
[Pages 19122-19123]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-9988]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Meeting

    Pursuant to Section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting of the National Cancer Institute Frederick Cancer Research and 
Development Center Advisory Committee.
    The open portion of the meeting will be limited to space available. 
Individuals who plan to attend and need special assistance, such as 
sign language interpretation or other reasonable accommodations, should 
notify the contact person in advance of the meeting.
    Committee Name: Frederick Cancer Research and Development Center 
Advisory Committee.
    Date: June 9-10, 1997.
    Place: Frederick Cancer Research and Development Center, Building 
549, Executive Board Room, Frederick, Maryland.
    Open: June 9--8:30 a.m.-10:00 a.m.
    Agenda: Discussion of administrative matters such as future 
meetings, budget, and information items related to the operation of the 
NCI Frederick Cancer Research and Development Center.
    Closed: June 9--10 a.m. to recess; June 10-8:30 a.m. to 
adjournment.
    Agenda/Purpose: Discussion of previous site visit report and 
response for the Molecular Virology and Carcinogenesis Laboratory 
review held December 17-18, 1996. The majority of the closed session 
will be devoted to a site review of the Gene Regulation and Chromosome 
Biology Laboratory with ABL-Basic Research Program Contract. Also 
included is a re-review of the Molecular Aspects of Drug Design 
Section, Macromolecular Structure Laboratory with ABL-Basic Research 
Program Contract.
    Contact Person: Cedric W. Long, Ph.D., Frederick Cancer Research 
and Development Center, P.O. Box B,

[[Page 19123]]

Frederick, MD 21702, Telephone: 301-846-1108.
    The meeting will be closed in accordance with the provisions set 
forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The report 
and the discussions could reveal confidential trade secrets or 
commercial property such as a patentable material and personal 
information concerning individuals associated with the programs, 
disclosure of which constitute a clearly unwarranted invasion of 
personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, 
Cancer Cause and Prevention Research; 93.394, Cancer Detection and 
Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, 
Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, 
Cancer Research Manpower; 93.399, Cancer Control)

    Dated: April 11, 1997.
LaVerne Y. Springfield,
Committee Management Officer, NIH.
[FR Doc. 97-9988 Filed 4-17-97; 8:45 am]
BILLING CODE 4140-01-M
xml version="1.0" encoding="UTF-8"?


C\_2019235EN.01000801.xml


| | | | |
| --- | --- | --- | --- |
| 12.7.2019 | EN | Official Journal of the European Union | C 235/8 |

---

Prior notification of a concentration

(Case M.9390 — Brookfield Asset Management/Oaktree Capital Group)

Candidate case for simplified procedure

(Text with EEA relevance)

(2019/C 235/06)

1.

On 5 July 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [(1)](#ntr1-C_2019235EN.01000801-E0001).

This notification concerns the following undertakings:

| | |
| --- | --- |
| — | Brookfield Asset Management Inc. (‘Brookfield’, USA), |

| | |
| --- | --- |
| — | Oaktree Capital Group Holdings, L.P. (‘OCGH’, USA), |

| | |
| --- | --- |
| — | Oaktree Capital Group, LLC (‘Oaktree’, USA). |

OCGH currently solely controls Oaktree. The concentration consists of Brookfield and OCGH acquiring joint control of Oaktree within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation.

The concentration is accomplished by way of purchase of shares.

2.

The business activities of the undertakings concerned are:

| | |
| --- | --- |
| — | Brookfield provides asset management services, focused on real estate, infrastructure, renewable power and private equity, |

| | |
| --- | --- |
| — | OCGH and Oaktree are part of the Oaktree Capital Group, a provider of asset management services focused mainly on corporate credit investment. |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 [(2)](#ntr2-C_2019235EN.01000801-E0002) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9390 — Brookfield Asset Management/Oaktree Capital Group

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

| |
| --- |
| E-mail: COMP-MERGER-REGISTRY@ec.europa.eu |
| Fax +32 22964301 |
| Postal address: |
| European Commission |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

---

[(1)](#ntc1-C_2019235EN.01000801-E0001)  [OJ L 24, 29.1.2004, p. 1](http://publications.europa.eu/resource/oj/JOL_2004_024_R_TOC) (the ‘Merger Regulation’).

[(2)](#ntc2-C_2019235EN.01000801-E0002)  [OJ C 366, 14.12.2013, p. 5](http://publications.europa.eu/resource/oj/JOC_2013_366_R_TOC).

---
##### 



(1)
    
    fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and(2)
    
    the information contained in the report fairly presents, in all material respects,
the financial condition and results of operations of The Lubrizol Corporation.
 /s/ James L. Hambrick

James L. Hambrick
Chief Executive Officer and President
May 4, 2007
  (1)
    
    fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and(2)
    
    the information contained in the report fairly presents, in all material respects,
the financial condition and results of operations of The Lubrizol Corporation.
 /s/ Charles P. Cooley

Charles P. Cooley
Chief Financial Officer
May 4, 2007
**Exhibit      32.2**

**CERTIFICATION      OF PRINCIPAL FINANCIAL & ACCOUNTING OFFICER**

**PURSUANT      TO 18 USC § 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE**

**SARBANES-OXLEY      ACT OF 2002**

|   | (1)      | The                Report fully complies with the requirements of Section 13(a) or 15(d),                as                applicable, of the Securities Exchange Act of 1934,                and |
|--------|-----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2)      | The                information contained in the Report fairly presents, in all material                respects, the financial condition and results of operations of the                Company                at the date and for the periods                indicated. |
|--------|-----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                      |   |   |                                                                                                                                  |
|-------------------------------------------|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------|
| Dated:                 March 4, 2008 |   |   | /s/                Xiaolin Zhuang                                                                                                     |
|                                      |   |   | Xiaolin                ZhuangChief Financial                Officer(Principal                Financial & Accounting Officer) |

----
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 97-6565

ANTHONY W. PANACCIONE,

Petitioner - Appellant,

versus

MICHAEL W. MOORE; STATE OF SOUTH CAROLINA;

CHARLES M. CONDON, Attorney General of the

State of South Carolina,

Respondents - Appellees.

Appeal from the United States District Court for the District of

South Carolina, at Charleston. Matthew J. Perry, Jr., Senior

District Judge. (CA-96-1688-10AJ)

Submitted: June 19, 1997 Decided: June 30, 1997

Before WILKINS and MICHAEL, Circuit Judges, and BUTZNER, Senior

Circuit Judge.

Dismissed by unpublished per curiam opinion.

Anthony W. Panaccione, Appellant Pro Se. Donald John Zelenka, Chief

Deputy Attorney General, Columbia, South Carolina, for Appellees.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
2

PER CURIAM:

Appellant seeks to appeal the district court's order denying

relief on his petition filed under 28 U.S.C.A. § 2254 (West 1994 &

Supp. 1997). We have reviewed the record and the district court's

opinion accepting the recommendation of the magistrate judge and

find no reversible error. Accordingly, we deny a certificate of appealability and dismiss the appeal on the reasoning of the district

court. Panaccione v. Moore, No. CA-96-1688-10AJ (D.S.C. Apr. 2,

1997). We dispense with oral argument because the facts and legal

contentions are adequately presented in the materials before the

court and argument would not aid the decisional process.

DISMISSED
xml version="1.0" encoding="UTF-8"?


C\_2019420EN.01002601.xml


| | | | |
| --- | --- | --- | --- |
| 13.12.2019 | EN | Official Journal of the European Union | C 420/26 |

---

Prior notification of a concentration

(Case M.9693 — Liberty/Aleris Divestment Business)

Candidate case for simplified procedure

(Text with EEA relevance)

(2019/C 420/10)

1.

On 4 December 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [(1)](#ntr1-C_2019420EN.01002601-E0001).

This notification concerns the following undertakings:

| | |
| --- | --- |
| — | Liberty House Group Pte. Ltd (‘Liberty’, Singapore) |

| | |
| --- | --- |
| — | Aleris Divestment Business (‘Aleris DB’, Belgium) |

Liberty acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the Aleris DB.

The concentration is accomplished by way of purchase of shares.

2.

The business activities of the undertakings concerned are:

| | |
| --- | --- |
| — | for Liberty: metals recycling, manufacture of steel, manufacture of aluminium and engineering products, |

| | |
| --- | --- |
| — | for Aleris DB: manufacture and sale of aluminium flat-rolled products, including in particular aluminium automotive body sheets and heat exchanger. |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 [(2)](#ntr2-C_2019420EN.01002601-E0002) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9693 — Liberty/Aleris Divestment Business

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| |
| --- |
| European Commission |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

---

[(1)](#ntc1-C_2019420EN.01002601-E0001)  [OJ L 24, 29.1.2004, p. 1](http://publications.europa.eu/resource/oj/JOL_2004_024_R_TOC) (the ‘Merger Regulation’).

[(2)](#ntc2-C_2019420EN.01002601-E0002)  [OJ C 366, 14.12.2013, p. 5](http://publications.europa.eu/resource/oj/JOC_2013_366_R_TOC).

---
|                                                                    
|--------------------------------------------------------------------
|                                                                    
|View History:  Monthly  Annual Download Data (XLS File)            
|View History:  Monthly  Annual                                      
|View History:  Monthly  Annual                                      
|View History:                                                       
|                                                                    
|Ohio Natural Gas Industrial Price  (Dollars per Thousand Cubic Feet)
|                                                                    
|                                                                    
|Ohio Natural Gas Industrial Price  (Dollars per Thousand Cubic Feet)
|                                                                    

|Decade                                                                                                                            | Year-0 | Year-1 | Year-2 | Year-3 | Year-4 | Year-5 | Year-6 | Year-7 | Year-8 | Year-9
|--------------------------------------------------------------------------------------------------------------------------------- | ------ | ------ | ------ | ------ | ------ | ------ | ------ | ------ | ------ | ------
|1990's                                                                                                                            |        |        |        |        |        |        |        | 4.93   | 4.39   | 3.94  
|2000's                                                                                                                            | 5.14   | 6.54   | 5.67   | 8.06   | 8.84   | 11.22  | 11.60  | 10.63  | 12.71  | 8.71  
|2010's                                                                                                                            | 7.40   | 6.77   | 5.48   | 6.03   | 7.06   | 5.35   | 4.81   | 6.71   | 6.57   | 6.21  
|2020's                                                                                                                            | 5.93   | 8.00   | 10.78  | 7.72   |        |        |        |        |        |       
|- = No Data Reported;  -- = Not Applicable;  NA = Not Available;  W = Withheld to avoid disclosure of individual company data.
|                                                                                                                                 
|Release Date: 5/31/2024                                                                                                          
|Next Release Date: 6/28/2024
IV 

112TH CONGRESS 

2D SESSION H. CON. RES. 133 

Authorizing the use of the rotunda of the United States Capitol for an 

event to present the Congressional Gold Medal to Arnold Palmer, in 

recognition of his service to the Nation in promoting excellence and 

good sportsmanship in golf. 

IN THE HOUSE OF REPRESENTATIVES 

JULY 17, 2012 

Mr. MURPHY of Pennsylvania submitted the following concurrent resolution; 

which was referred to the Committee on House Administration 

CONCURRENT RESOLUTION 

Authorizing the use of the rotunda of the United States 

Capitol for an event to present the Congressional Gold 

Medal to Arnold Palmer, in recognition of his service 

to the Nation in promoting excellence and good sportsmanship in golf. 

1 Resolved by the House of Representatives (the Senate 

2 concurring), 

3 SECTION 1. USE OF THE ROTUNDA OF THE UNITED STATES 

4 CAPITOL TO PRESENT THE CONGRESSIONAL 

5 GOLD MEDAL. 

6 (a) AUTHORIZATION.—The rotunda of the United 

7 States Capitol is authorized to be used on September 12, 


jbell on DSK7SPTVN1PROD with BILLS
2 

•HCON 133 IH 

1 2012, for the presentation of the Congressional Gold 

2 Medal to Arnold Palmer, in recognition of his service to 

3 the Nation in promoting excellence and good sportsman4 ship in golf. 

5 (b) PREPARATIONS.—Physical preparations for the 

6 conduct of the event described in subsection (a) shall be 

7 carried out in accordance with such conditions as may be 

8 prescribed by the Architect of the Capitol. 

Æ 


jbell on DSK7SPTVN1PROD with BILLS
# C_2019392EN.01001201.xml

| 19.11.2019 | EN | Official Journal of the European Union | C 392/12 |
| --- | --- | --- | --- |

19.11.2019

EN

Official Journal of the European Union

C 392/12

---

Prior notification of a concentration

(Case M.9461 — AbbVie/Allergan)

(Text with EEA relevance)

(2019/C 392/11)

1.

This notification concerns the following undertakings:

| — | AbbVie Inc., (‘AbbVie’, United States), |
| --- | --- |

—

AbbVie Inc., (‘AbbVie’, United States),

| — | Allergan plc (‘Allergan’, Ireland). |
| --- | --- |

—

Allergan plc (‘Allergan’, Ireland).

AbbVie acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Allergan.

The concentration is accomplished by way of purchase of shares.

2.

| — | AbbVie is a global pharmaceutical company listed on the New York Stock Exchange and headquartered in the United States. AbbVie is engaged in the development and commercialisation of innovative medicines in six main therapeutic areas: immunology (including autoimmune diseases), oncology, virology, neuroscience/central nervous system disorders, metabolic diseases and pain associated with endometriosis; |
| --- | --- |

—

AbbVie is a global pharmaceutical company listed on the New York Stock Exchange and headquartered in the United States. AbbVie is engaged in the development and commercialisation of innovative medicines in six main therapeutic areas: immunology (including autoimmune diseases), oncology, virology, neuroscience/central nervous system disorders, metabolic diseases and pain associated with endometriosis;

| — | Allergan is a global pharmaceutical company listed on the New York Stock Exchange and headquartered in Ireland. Allergan is engaged in the development and commercialisation of medicines in four key therapeutic areas: medical aesthetics, eye care, neuroscience/central nervous system disorders and gastroenterology. |
| --- | --- |

—

Allergan is a global pharmaceutical company listed on the New York Stock Exchange and headquartered in Ireland. Allergan is engaged in the development and commercialisation of medicines in four key therapeutic areas: medical aesthetics, eye care, neuroscience/central nervous system disorders and gastroenterology.

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9461 — AbbVie/Allergan

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| European Commission |
| --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---